The rexinoid bexarotene represses cyclin D1 transcription by inducing the DEC2 transcriptional repressor.
Bexarotene is an RXR-selective vitamin A analog that has been shown to prevent ER-negative mammary tumorigenesis in animal models. While investigating the mechanism by which bexarotene prevents ER-negative breast cancer development, we found that the expression of cyclin D1, a critical cell cycle promoter, was repressed by bexarotene in vitro and in vivo. Time course and cycloheximide experiments show that repression of cyclin D1 is a late effect and requires new protein synthesis. Previously we discovered that DEC2 (differentially expressed in chondrocytes-2), a helix-loop-helix transcription repressor, was induced by bexarotene in human mammary epithelial cells. Therefore, we hypothesized that bexarotene represses the transcription of cyclin D1 through induction of DEC2. Luciferase reporter studies demonstrated that either bexarotene treatment or forced expression of DEC2 can repress the transcription of a cyclin D1 promoter reporter by affecting the basal transcriptional activity. Results from chromatin immunoprecipitation experiments showed that bexarotene treatment causes the recruitment of DEC2 and HDAC1 (histone deacetylase 1) to the cyclin D1 promoter. Co-immunoprecipitation confirms the interaction between DEC2 and HDAC1, suggesting that the recruitment of HDAC1 to the cyclin D1 promoter is through DEC2. Trichostatin A, a HDAC inhibitor, reverses the cyclin D1 repression by bexarotene, suggesting that repression of cyclin D1 involves histone deacetylation. Knock-down of DEC2 by siRNA abolishes the cyclin D1 repression, further supporting our hypothesis. Finally, we demonstrated that overexpression of DEC2 dramatically inhibited cell proliferation and repressed the expression of cyclin D1 in human mammary epithelial cells. These results suggest that bexarotene down-regulates cyclin D1 through induction of DEC2, followed by recruitment of HDAC1 to the cyclin D1 promoter causing transcriptional repression. By elucidating the mechanism by which rexinoids inhibit cell proliferation, it will be possible to develop more effective and less toxic drugs to prevent ER-negative breast cancers.
Li
Yuxin
Y
Department of Clinical Cancer Prevention, The University of Texas, Anderson Cancer Center Cancer, Houston, TX 77030, USA.
Shen
Qiang
Q
Kim
Hee-Tae
HT
Bissonnette
Reid P
RP
Lamph
William W
WW
Yan
Bingfang
B
Brown
Powel H
PH
D051792:Basic Helix-Loop-Helix Proteins / Q000235:genetics* / Q000378:metabolism*; D000077610:Bexarotene; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D019938:Cyclin D1 / Q000235:genetics*; D004268:DNA-Binding Proteins / Q000235:genetics / Q000378:metabolism; D015536:Down-Regulation / Q000187:drug effects / Q000235:genetics; D004847:Epithelial Cells / Q000378:metabolism; D005786:Gene Expression Regulation / Q000187:drug effects; D006655:Histone Deacetylases / Q000378:metabolism; D006801:Humans; D042361:Mammary Glands, Human / Q000378:metabolism; D008954:Models, Biological; D011401:Promoter Regions, Genetic / Q000187:drug effects; D013764:Tetrahydronaphthalenes / Q000494:pharmacology*; D014158:Transcription, Genetic / Q000187:drug effects*
D051792:Basic Helix-Loop-Helix Proteins; D000077610:Bexarotene; D019938:Cyclin D1; D004268:DNA-Binding Proteins; D006655:Histone Deacetylases; D013764:Tetrahydronaphthalenes; C422085:BHLHE41 protein, human
JAMA. 2006 Jun 21;295(23):2727-41
16754727
J Biol Chem. 1995 Oct 6;270(40):23589-97
7559524
Breast Cancer Res Treat. 2006 Mar;96(2):147-57
16273314
J Biol Chem. 2000 Jun 2;275(22):17149-53
10747926
Mol Pathol. 1998 Feb;51(1):1-7
9624412
Oncogene. 2002 Oct 31;21(50):7680-9
12400010
Cancer Cell. 2006 Jan;9(1):23-32
16413469
Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4058-63
10737769
Cancer Res. 2005 Apr 15;65(8):3462-9
15833882
Cancer Res. 2006 Dec 15;66(24):12009-18
17178900
Cancer Res. 2002 Nov 15;62(22):6376-80
12438218
Genes Dev. 1997 Aug 15;11(16):2052-65
9284045
Biochem Biophys Res Commun. 2001 Jan 12;280(1):164-71
11162494
Oncogene. 2006 Jun 1;25(23):3296-306
16462771
Br J Cancer. 2008 Apr 22;98(8):1380-8
18362934
Biochem Biophys Res Commun. 1997 Jul 18;236(2):294-8
9240428
Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2848-53
11880636
Cancer Cell. 2006 Jan;9(1):13-22
16413468
J Biol Chem. 2003 May 9;278(19):16899-907
12624110
J Biol Chem. 2003 May 30;278(22):20098-109
12657651
Clin Cancer Res. 2007 Mar 15;13(6):1794-800
17363535
J Mammary Gland Biol Neoplasia. 1999 Oct;4(4):377-88
10705921
Oncogene. 1994 Apr;9(4):1295-304
8134134
Biochem J. 2004 Sep 15;382(Pt 3):895-904
15193144
Mol Endocrinol. 2005 Feb;19(2):362-78
15514030
J Biol Chem. 2004 Dec 10;279(50):52643-52
15448136
Cancer Epidemiol Biomarkers Prev. 2002 May;11(5):467-74
12010861
Biochem J. 2002 Oct 15;367(Pt 2):413-22
12119049
Clin Cancer Res. 2007 Oct 15;13(20):6224-31
17947490
Clin Cancer Res. 2000 Sep;6(9):3696-704
10999763
Lancet. 2003 Jan 25;361(9354):296-300
12559863
Int J Mol Med. 2007 Jun;19(6):925-32
17487425